Isis Pharma earns $2.15 million from Biogen

15 July 2015

Isis Pharmaceuticals (Nasdaq: ISIS) says it has earned a $2.15 million milestone payment from Biogen (Nasdaq: BIIB) related to advancing the ongoing pivotal Phase III study (CHERISH) evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).

To date, Isis has generated more than $120 million in payments from Biogen related to the development of ISIS-SMNRx, as part of a collaboration that could be worth as much as $299 million (The Pharma Letter January 5, 2012). Isis shares rose 4.95% to $56.35 on the news yesterday.

CHERISH, a Phase III study of ISIS-SMNRx, is a randomized, double-blind, sham-procedure controlled 15-month study in around 120 children who are non-ambulatory with SMA between the ages of two to 12. The study will evaluate the efficacy and safety of 12mg doses of ISIS-SMNRx with a primary endpoint of a change in the Hammersmith Functional Motor Scale-Expanded (HFMSE), a validated method to measure changes in muscle function in patients with SMA. Additional efficacy endpoints are also included in the study.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK